Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 472

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers

Open access
Stanworth, Simon J., Estcourt, Lise J., Powter, Gillian, Kahan, Brennan C., Dyer, Claire, Choo, Louise, Bakrania, Lekha, Llewelyn, Charlotte, Littlewood, Timothy, Soutar, Richard, Norfolk, Derek, Copplestone, Adrian, Smith, Neil, Kerr, Paul, Jones, Gail, Raj, Kavita, Westerman, David A., Szer, Jeffrey, Jackson, Nicholas, Bardy, Peter G., Plews, Dianne, Lyons, Simon, Bielby, Linley, Wood, Erica M., Murphy, Michael F.·2013·New England Journal of Medicine

Abstract

BACKGROUND: The effectiveness of platelet transfusions to prevent bleeding in patients with hematologic cancers remains unclear. This trial assessed whether a policy of not giving prophylactic platelet transfusions was as effective and safe as a policy of providing prophylaxis. METHODS: We conducted this randomized, open-label, noninferiority trial at 14 centers in the United Kingdom and Australia. Patients were randomly assigned to receive, or not to receive, prophylactic platelet transfusions when morning platelet counts were less than 10×10(9) per liter. Eligible patients were persons 16 years of age or older who were receiving chemotherapy or undergoing stem-cell transplantation and who had or were expected to have thrombocytopenia. The primary end point was bleeding of World Health Organization (WHO) grade 2, 3, or 4 up to 30 days after randomization. RESULTS: A total of 600 patients (301 in the no-prophylaxis group and 299 in the prophylaxis group) underwent randomization between 2006 and 2011. Bleeding of WHO grade 2, 3, or 4 occurred in 151 of 300 patients (50%) in the no-prophylaxis group, as compared with 128 of 298 (43%) in the prophylaxis group (adjusted difference in proportions, 8.4 percentage points; 90% confidence interval, 1.7 to 15.2; P=0.06 for noninferiority). Patients in the no-prophylaxis group had more days with bleeding and a shorter time to the first bleeding episode than did patients in the prophylaxis group. Platelet use was markedly reduced in the no-prophylaxis group. A prespecified subgroup analysis identified similar rates of bleeding in the two study groups among patients undergoing autologous stem-cell transplantation. CONCLUSIONS: The results of our study support the need for the continued use of prophylaxis with platelet transfusion and show the benefit of such prophylaxis for reducing bleeding, as compared with no prophylaxis. A significant number of patients had bleeding despite prophylaxis. (Funded by the National Health Service Blood and Transplant Research and Development Committee and the Australian Red Cross Blood Service; TOPPS Controlled-Trials.com number, ISRCTN08758735.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1212772

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 472

Metadata

Authors
Stanworth, S. J., Estcourt, L. J., Powter, G., Kahan, B. C., Dyer, C., Choo, L., Bakrania, L., Llewelyn, C., Littlewood, T., Soutar, R., Norfolk, D., Copplestone, A., Smith, N., Kerr, P., Jones, G., Raj, K., Westerman, D. A., Szer, J., Jackson, N., Bardy, P. G., Plews, D., Lyons, S., Bielby, L., Wood, E. M., & Murphy, M. F.
Venue
New England Journal of Medicine
Published
2013-05-09
Volume
368
Issue
19
Pages
1771-1780
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2074120475
Cited by
472
References
14
FWCI
27.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. https://app.cochat.ai/papers/10.1056/nejmoa1212772
The paper
Stanworth, S. J., Estcourt, L. J., Powter, G., Kahan, B. C., Dyer, C., Choo, L., Bakrania, L., Llewelyn, C., Littlewood, T., Soutar, R., Norfolk, D., Copplestone, A., Smith, N., Kerr, P., Jones, G., Raj, K., Westerman, D. A., Szer, J., Jackson, N., . . . Murphy, M. F. (2013). A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1212772

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.